-
Je něco špatně v tomto záznamu ?
CHEK2 variant I157T may be associated with increased breast cancer risk
O Kilpivaara, P Vahteristo, J Falck, K Syrjakoski, H Eerola, D Easton, J Bartkova, J Lukas, P Heikkila, K Aittomaki, K Holli, C Blomqvist, OP Kallioniemi, J Bartek, H Nevanlinna
Jazyk angličtina Země Spojené státy americké
PubMed
15239132
Knihovny.cz E-zdroje
- MeSH
- checkpoint kinasa 2 MeSH
- genetická predispozice k nemoci * MeSH
- imunohistochemie MeSH
- lidé MeSH
- nádory prsu * etiologie genetika MeSH
- odds ratio MeSH
- poškození DNA MeSH
- protein-serin-threoninkinasy * genetika MeSH
- replikace DNA MeSH
- studie případů a kontrol MeSH
- tolerance záření MeSH
- tumor supresorové geny MeSH
- zárodečné mutace * MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
Cell cycle checkpoint kinase 2 (CHEK2) is a transducer of cellular responses to DNA damage. The CHEK2 1100delC has previously been shown to be a low-penetrance breast cancer susceptibility allele. We have evaluated the role of another CHEK2 variant, I157T in the FHA domain of the gene, for association with breast cancer. I157T was found at a significantly higher frequency in the population-based series of breast cancer patients (77/1035, 7.4%, odds ratio [OR] = 1.43, 95% confidence interval [CI] = 1.06-1.95, p = 0.021) than among population controls (100/1885, 5.3%). The frequency in the familial breast cancer patients was not elevated (28/507, 5.5%, OR = 1.04, 95% CI = 0.68-1.61). The I157T protein, that undermines cellular responses to ionizing radiation and shows deficiency in substrate recognition in vivo, was expressed at normal level in tumor tissues as well as in cultured cells. The I157T protein was stable and it dimerized with the wild-type CHEK2 co-expressed in human cells. These functional properties of the I157T protein suggest that this variant may have negative effect on the pool of normal CHEK2 protein in heterozygous carrier cells by formation of heterodimers with wild-type CHEK2. The I157T variant may be associated with breast cancer risk, but the risk is lower than for 1100delC. Copyright 2004 Wiley-Liss, Inc.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14079637
- 003
- CZ-PrNML
- 005
- 20141120105756.0
- 007
- ta
- 008
- 141120s2004 xxu f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)15239132
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kilpivaara, O. $u Department of Obstetrics and Gynecology, Helsinki University Central Hospital (HUCH), Helsinki, Finland.
- 245 10
- $a CHEK2 variant I157T may be associated with increased breast cancer risk / $c O Kilpivaara, P Vahteristo, J Falck, K Syrjakoski, H Eerola, D Easton, J Bartkova, J Lukas, P Heikkila, K Aittomaki, K Holli, C Blomqvist, OP Kallioniemi, J Bartek, H Nevanlinna
- 520 9_
- $a Cell cycle checkpoint kinase 2 (CHEK2) is a transducer of cellular responses to DNA damage. The CHEK2 1100delC has previously been shown to be a low-penetrance breast cancer susceptibility allele. We have evaluated the role of another CHEK2 variant, I157T in the FHA domain of the gene, for association with breast cancer. I157T was found at a significantly higher frequency in the population-based series of breast cancer patients (77/1035, 7.4%, odds ratio [OR] = 1.43, 95% confidence interval [CI] = 1.06-1.95, p = 0.021) than among population controls (100/1885, 5.3%). The frequency in the familial breast cancer patients was not elevated (28/507, 5.5%, OR = 1.04, 95% CI = 0.68-1.61). The I157T protein, that undermines cellular responses to ionizing radiation and shows deficiency in substrate recognition in vivo, was expressed at normal level in tumor tissues as well as in cultured cells. The I157T protein was stable and it dimerized with the wild-type CHEK2 co-expressed in human cells. These functional properties of the I157T protein suggest that this variant may have negative effect on the pool of normal CHEK2 protein in heterozygous carrier cells by formation of heterodimers with wild-type CHEK2. The I157T variant may be associated with breast cancer risk, but the risk is lower than for 1100delC. Copyright 2004 Wiley-Liss, Inc.
- 590 __
- $a bohemika - dle Pubmed
- 650 12
- $a nádory prsu $x etiologie $x genetika $7 D001943
- 650 02
- $a studie případů a kontrol $7 D016022
- 650 02
- $a checkpoint kinasa 2 $7 D064447
- 650 02
- $a poškození DNA $7 D004249
- 650 02
- $a replikace DNA $7 D004261
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a tumor supresorové geny $7 D016147
- 650 12
- $a genetická predispozice k nemoci $7 D020022
- 650 12
- $a zárodečné mutace $7 D018095
- 650 02
- $a lidé $7 D006801
- 650 02
- $a imunohistochemie $7 D007150
- 650 02
- $a odds ratio $7 D016017
- 650 12
- $a protein-serin-threoninkinasy $x genetika $7 D017346
- 650 02
- $a tolerance záření $7 D011836
- 700 1_
- $a Vahteristo, P.
- 700 1_
- $a Falck, J.
- 700 1_
- $a Syrjakoski, K.
- 700 1_
- $a Eerola, H.
- 700 1_
- $a Easton, D.
- 700 1_
- $a Bártková, Jiřina $7 xx0094304
- 700 1_
- $a Lukáš, Jiří $7 xx0094305
- 700 1_
- $a Heikkila, P.
- 700 1_
- $a Aittomaki, K. $7 gn_A_00002739
- 700 1_
- $a Holli, K.
- 700 1_
- $a Blomqvist, C.
- 700 1_
- $a Kallioniemi, OP..
- 700 1_
- $a Bártek, Jiří, $d 1953- $7 xx0046271
- 700 1_
- $a Nevanlinna, H.
- 773 0_
- $t International Journal of Cancer $x 0020-7136 $g Roč. 111, č. 4 (2004), s. 543-547 $p Int J Cancer $w MED00002298
- 773 0_
- $p Int J Cancer $g 111(4):543-7, 2004 Sep 10 $x 0020-7136
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20141120105837 $b ABA008
- 991 __
- $a 20141120105837 $b ABA008
- 999 __
- $a ok $b bmc $g 1047982 $s 878656
- BAS __
- $a 3
- BMC __
- $a 2004 $b 111 $c 4 $d 543-547 $x MED00002298 $i 0020-7136 $m International journal of cancer $n Int J Cancer
- LZP __
- $a NLK 2014-1/lp